Evidence map›Paper›PMID 26228813›Full record

ArticleLeukemia2015

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S K Metzelder, S Spoerl, M Ditschkowski, M Ecsedi, K Sockel and 43 more

4 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 266 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 9 pooled it
33.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02997280 phase2completednot on this mapstarted 2016, after this paper: background citation

Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases

TypeinterventionalSponsorSt. Petersburg State Pavlov Medical UniversityRan2016 to 2019Enrolled75ConditionsGraft Vs Host DiseaseArmsRuxolitinib Oral Tablet
NCT03395340 phase2terminatednot on this mapstarted 2018, after this paper: background citation

Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

TypeinterventionalSponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Ran2018 to 2019Enrolled1ConditionsGraft Versus Host Disease, JNS Kinase, Topical AdministrationArmsRuxolitinib 1.5% cream, vehicle cream
NCT04342442 completednot on this mapstarted 2017, after this paper: background citation

Investigation of Novel Targetable Kinases in Steroid-refractory Acute Graft-versus-host Disease

TypeobservationalSponsorUniversity of FreiburgRan2017 to 2019Enrolled24ConditionsGraft Versus Host Disease
NCT04397367 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Low Dose Ruxolitinib in Combination With Methylprednisolone 1mg/kg as Initial Therapy for Acute Graft-Versus-Host Disease

TypeinterventionalSponsorChinese PLA General HospitalRan2019 to 2020Enrolled38ConditionsaGVHD, Stem Cell Transplant ComplicationsArmsRuxolitinib 10 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg once a day combined with Corticosteroids, Ruxolitinib 2.5 mg once a day combined with Corticosteroids
3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 9 syntheses or guidelines pooled it, 536 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.Journal of cellular and molecular medicine · 2021
    Trial
  20. Trial

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 7 countries.

R ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
A BurchertDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, and University Medical Center Giessen and Marburg, Marburg, Germany.
C LengerkeDivision of Hematology, University Hospital of Basel, Basel, Switzerland.
M VerbeekIII Department of Internal Medicine, Technical University of Munich, Munich, Germany.
K Maas-BauerDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
S K MetzelderDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, and University Medical Center Giessen and Marburg, Marburg, Germany.
S SpoerlIII Department of Internal Medicine, Technical University of Munich, Munich, Germany.
M DitschkowskiDepartment of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
M EcsediDivision of Hematology, University Hospital of Basel, Basel, Switzerland.
K SockelDepartment of Hematology and Oncology, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany.
F AyukDepartment of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
S AjibDepartment of Internal Medicine II, University Hospital, Frankfurt/Main, Germany.
F S de FontbruneHematology Stem cell transplant Unit, Saint Louis Hospital, APHP, Paris, France.
I-K NaDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
L PenterDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
U HoltickDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
D WolfMedical Clinic III, Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
E SchulerDepartment of Hematology, Oncology and Clinical Immunology, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
E MeyerDepartment of Bone Marrow Transplantation, Stanford University Medical School, Stanford, CA, USA.
P ApostolovaDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
H BertzDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
R MarksDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
M LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
R WäschDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
C ScheidDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
F StölzelDepartment of Hematology and Oncology, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany.
R OrdemannDepartment of Hematology and Oncology, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany.
G BugDepartment of Internal Medicine II, University Hospital, Frankfurt/Main, Germany.
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
R NegrinDepartment of Bone Marrow Transplantation, Stanford University Medical School, Stanford, CA, USA.
M BruneDepartment of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
A SpyridonidisDepartment of Bone Marrow Transplantation, Patras University Medical School, Patras, Greece.
A Schmitt-GräffDepartment of Pathology, Freiburg University Medical Center, Freiburg, Germany.
W van der VeldenRadboud University Medical Centre, Nijmegen, The Netherlands.
G HulsRadboud University Medical Centre, Nijmegen, The Netherlands.
S MielkeDepartment of Hematology and Oncology, University Medical Centre Würzburg, Würzburg, Germany.
G U GrigoleitDepartment of Hematology and Oncology, University Medical Centre Würzburg, Würzburg, Germany.
J KuballDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
R FlynnDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
G IhorstClinical Trials Unit, Department of Hematology, Freiburg University Medical Center, Freiburg, Germany.
J DuDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
B R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
R ArnoldDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
N KrögerDepartment of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
J PasswegDivision of Hematology, University Hospital of Basel, Basel, Switzerland.
J HalterDivision of Hematology, University Hospital of Basel, Basel, Switzerland.
G SociéHematology Stem cell transplant Unit, Saint Louis Hospital, APHP, Paris, France.
D BeelenDepartment of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
C PeschelIII Department of Internal Medicine, Technical University of Munich, Munich, Germany.
A NeubauerDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, and University Medical Center Giessen and Marburg, Marburg, Germany.
J FinkeDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
J DuysterDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
N von BubnoffDepartment of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
University Medical Center Freiburg · DEUniversity Hospital of Basel · CHCharité - Universitätsmedizin Berlin · DETechnical University of Munich · DEUniversitätsklinikum Gießen und Marburg · DEUniversity of Minnesota · USAssistance Publique – Hôpitaux de Paris · FREssen University Hospital · DERadboud University Medical Center · NLStanford University · USUniversitätsklinikum Würzburg · DEUniversity Hospital Cologne · DEDüsseldorf University Hospital · DEGoethe University Frankfurt · DEHeinrich Heine University Düsseldorf · DEUniversität Hamburg · DEUniversity Hospital Bonn · DEUniversity Hospital Frankfurt · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Center Utrecht · NL

Funding

Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
NCI NIH HHS P01 CA142106NIAID NIH HHS R01 AI034495
6 · The paper itself

Abstract

Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n=54, all grades III or IV) or SR-cGVHD (n=41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1-7) and SR-cGVHD (1-10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3-90.7%, 95% confidence interval (CI)) and 97.4% (92.3-100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.

Indexed as

Salvage TherapyAdrenal Cortex HormonesAdultAgedAnimalsDisease Models, AnimalDrug Resistance, NeoplasmFemaleFollow-Up StudiesGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansJanus KinasesMaleMiceAdrenal Cortex HormonesJanus KinasesNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID26228813
PMCPMC4854652
OpenAlexW1870543278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.